Overview

CytoSorbents Investor Relations

CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with >270,000 CytoSorb devices sold in 70+ countries to date, and with applications to FDA and Health Canada for DrugSorb-ATR marketing approval under review.

Featured News

CytoSorbents

Press Release

13 Nov '25

CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with an additional $2.5 million of cash, and extends the interest only-period through December 31, 2026, with an additional $2.5 million available and an additional extension of the interest-only period to June 30, ... CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

11 Nov '25

CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

PRINCETON, N.J., Nov. 11, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that its Chief Executive Officer, Dr. Phillip Chan, and Chief Financial Officer, Mr. Peter Mariani, will attend and participate in one-on-one meetings with ... CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

30 Oct '25

CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

PRINCETON, N.J., Oct. 30, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business highlights after the market close on Thursday, November 13, 2025. CytoSorbents’ management will host a ... CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

29 Sep '25

CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

PRINCETON, N.J., Sept. 29, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today its strong scientific presence at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting, the world’s largest gathering for the global cardiothoracic ... CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

View All News